Hypophosphatemia associated with use of intravenous ferric carboxymaltose

• Published in: Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral Vol. 40; no. 6; pp. 1301 - 1304
• Main Authors: Proaño Fierro, María Esther, Rodríguez Cañete, Blanca Leticia, Sánchez Sobrino, Paula, Rego Iraeta, Antonia Lourdes
• Format: Journal Article
• Language: English; Spanish
• Published: Spain 14-12-2023
• Subjects: Hipofosfatemia. Carboximaltosa férrica. FGF-23. Fosfaturia
• ISSN: 0212-1611; 1699-5198
• DOI: 10.20960/nh.04806

Introduction: ferric carboxymaltose (CF) is an intravenous preparation that helps the rapid correction of anemia with a lower risk of adverse reactions. However, an association has been found between the administration of CF and the development of hypophosphatemia. Case report: we present the clinical case of a 57-year-old patient with a history of iron de-ficiency anemia who, after receiving treatment with CF (Ferinjet®) chronically, develops a clinical of severe muscle weakness. Laboratory tests showed hypophosphatemia, normocalcemia, normal vitamin D level (after correction) and increased renal excretion of phosphorus. After study, the diagnosis of chronic hypophosphatemia secondary to the use of CF is reached. Discussion: CF can cause an increase in FGF-23 which acts at the renal level inducing phosphaturia, which can generate severe hypophosphatemia. This case demonstrates the importance of recognizing and treating this clinical entity in time.